Top

Published in:

Open Access 23-07-2022 | Systemic Lupus Erythematosus | Original Article

Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients

Authors: Carlos Rodríguez Escalera, Ángela María Zurita Guisado, Francisco Javier Mateo, Noemí Bahamontes-Rosa, María Jesús García Villanueva

Published in: Clinical Rheumatology | Issue 11/2022

Abstract

Background

Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is not a review focusing on all real-life experience with belimumab to date that could help to describe how this drug behaves in the Spanish clinical setting.

Objective

To describe the characteristics of SLE patients treated with belimumab added to standard of care in real-clinical setting in Spain.

Methods

We conducted a comprehensive scoping review of real-world data (RWD) according to PRISMA Scoping Reviews Checklist and the framework proposed by Arksey and O’Malley. PubMed and EMBASE were searched without language restriction and hand searches of relevant articles were examined.

Results

We included data from 222 patients treated with belimumab for SLE included in 19 RWD studies conducted in Spain. The mean age was 40.9 years, 84.2% were female, and baseline scores SELENA-SLEDAI ranged between 5.9 and 12. Lupus nephritis basal prevalence was of 2.7%. The main reason for belimumab initiation was previous treatments lack of efficacy (69.7%) and the most common laboratory abnormalities were hypocomplementemia (40.9%), ANA + (34.2%), and anti-DNA (33.3%). The addition of belimumab to standard therapy was associated with a reduction of daily glucocorticoids intake in 1.4–11.1 mg at 6 months. Belimumab discontinuation was observed in 18.6% of patients.

Conclusion

Our study helps to further explore the profile of SLE patients most likely to be treated with belimumab.

Key Points

• Scientific evidence in SLE provided by randomized controlled trials sometimes differs from the actual treatment of SLE patients in routine clinical practice.

• There is a lack of published “real-world” data on SLE treatment with belimumab in Spain.

• This scoping review intends to describe and analyze the clinical characteristics of SLE patients receiving belimumab in a real-life setting in Spain.

• These “real-world” clinical experience can provide a more realistic view of the overall patterns of SLE care compared with clinical trials.

Available only for authorised users

Yazdany J, Dall’Era M (2018) Definition and classification of lupus and lupus-related disorders. Dubois’ Lupus Erythematosus and Related Syndromes. Elsevier :15–22. https://doi.org/10.1016/B978-0-323-47927-1.00002-5

Alonso MD, Llorca J, Martinez-Vazquez F et al (2011) Systemic lupus erythematosus in Northwestern Spain: a 20-year epidemiologic study. Med (Baltimore) 90(5):350–358CrossRef

López P, Mozo L, Gutiérrez C, Suárez A (2003) Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus 12(11):860–865CrossRef

Stoll T (2004) Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus–a 5-yr prospective study. Rheumatol 43(8):1039–1044. https://doi.org/10.1093/rheumatology/keh238CrossRef

Yurkovich M, Vostretsova K, Chen W, Aviña-Zubieta JA (2014) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 66(4):608–616. https://doi.org/10.1002/acr.22173CrossRef

Yen EY, Singh RR (2018) Brief report: lupus—an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000–2015. Arthritis Rheumatol 70(8):1251–1255CrossRef

Bertsias G, Ioannidis JPA, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67(2):195–205CrossRef

Oglesby A, Shaul AJ, Pokora T et al (2013) Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. Int J Rheumatol 2013:1–9.http://www.hindawi.com/journals/ijr/2013/347520/

Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30(9):1955–1959PubMed

10.

CHMP_Benlysta (2021) Annex i summary of product characteristics: belimumab. https://www.ema.europa.eu/en/documents/product-information/benlysta-epar-product-information_en.pdf. Accessed April 2021

11.

Tesar V, Hruskova Z (2017) Belimumab in the management of systemic lupus erythematosus–an update. Expert Opin Biol Ther 17(7):901–908CrossRef

12.

Furie R, Rovin BH, Houssiau F et al (2020) Two-year randomized controlled trial of belimumab in lupus nephritis. N Engl J Med 383(12):1117–1128. https://doi.org/10.1056/NEJMoa2001180CrossRefPubMed

13.

Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS (2008) Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatol 48(5):542–545. https://doi.org/10.1093/rheumatology/kep012CrossRef

14.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT et al (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res 61(9):1168–1178CrossRef

15.

Furie R, Petri M, Zamani O, Cervera R et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–3930CrossRef

16.

Navarra SV, Guzmán RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721–731CrossRef

17.

Furie R, Stohl W, Ginzler EM et al (2008) Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 10:5CrossRef

18.

Doria A, Iaccarino L, Ghirardello A et al (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med119(8):700–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002934306001938

19.

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467. https://doi.org/10.7326/M18-0850CrossRefPubMed

20.

Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract 8(1):19–32CrossRef

21.

Levac D, Colquhoun H, O’Brien KK (2010) Scoping studies: advancing the methodology. Implement Sci 5(1):69. https://doi.org/10.1186/1748-5908-5-69CrossRefPubMedPubMedCentral

22.

Cortes J, Marras C, Andreu JL, Calvo-Alen J, Garcia-Aparicio AM, Alvarez Diez E, et al (2014) Evolution of patients with systemic lupus erythematous treated with belimumab in clinical practice settings (Observe Study). 2014 ACR/ARHP Annu Meet S291. https://doi.org/10.1016/j.jval.2014.08.1703

23.

la Navarro MD, R, Arévalo K, Chalmeta I, et al (2018) PS7:147 Clinical experience of belimumab treatment in clinical practice of sle patients. Lupus Sci Med 5(Suppl 1):A108–A108

24.

Navarro MD la R, Checa SC, Cortés JI et al (2019) AB0463 belimumab iv effect in glucocorticoid treatment in systemic lupus erythematosus patients. Annals of the Rheumatic Diseases 78(Suppl 2):1695.2–1696. https://doi.org/10.1136/annrheumdis-2019-eular.6585

25.

Cortés J, Andreu JL, Calvo J, García-Aparicio AM, Coronell CG, Díaz-Cerezo S (2019) Evaluation of use of belimumab in clinical practice settings (observe study) in Spain: health resource utilization and labour absenteeism. Value Health. https://doi.org/10.1016/j.jval.2014.08.1703CrossRef

26.

Carrión-Barberà I, Salman-Monte TC, Castell S, Castro-Domínguez F, Ojeda F, Monfort J (2019) Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab: a case report and literature review. Eur J Rheumatol 1–3. http://www.ncbi.nlm.nih.gov/pubmed/31329542

27.

Gonzalez-Echavarri C, Ugarte A, Ruiz-Irastorza G (2016) Rituximab-refractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol 34(2):355–356PubMed

28.

Giménez AR, Pastrana DB, Huaranga MAR et al (2019) Belimumab in refractory organizing pneumonia associated with systemic lupus erythematosus: a case report. Lupus 28(4):565–568. https://doi.org/10.1177/0961203319835320CrossRefPubMed

29.

Carbajal S, Zamora-Martínez C, Prieto-González S, Quintana L, Espinosa G, Cervera R (2019) Systemic lupus erythematous exacerbation following cessation of belimumab treatment: comments on the article by Furer et al. Scand J Rheumatol 46(3):250–251. https://doi.org/10.1080/03009742.2016.1264626CrossRef

30.

Husein-ElAhmed H, Callejas-Rubio J, Rios-Fernandez R, Ortego-Centeno N (2019) Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody. Indian J Dermatology, Venereol Leprol 80(5):477. http://www.ijdvl.com/text.asp?2014/80/5/477/140335

31.

Castillo Dayer PV, Lozano Rivas N, Martínez Ferrín JJ, Victoria Martínez AM, Sánchez‐Pedreño Guillen P, Marras Fernández‐Cid C (2019) Belimumab treatment in rhupus: a case report with severe skin involvement. Dermatol Ther 32(5):e13056. http://www.ncbi.nlm.nih.gov/pubmed/31393634

32.

Moriano C, Garijo M, Iñiguez C, et al (2018) AB0507 Belimumab in patients with systemic lupus erythematosus: outcomes in routine clinical practice. In: SLE, Sjögren’s and APS – treatment. BMJ Publishing Group Ltd and European League Against Rheumatism 77 (Suppl 2). 1413.1–1413. https://doi.org/10.1136/annrheumdis-2018-eular.7530

33.

M Lorente XB y el grupo A-M (2018) Resultado a largo plazo del tratamiento periódico con Belimumab en pacientes con LES: datos de práctica clínica.

34.

Hernandez-Flόrez D, Valor L, Del Río T et al (2015) AB0520 evaluating the effect of belimumab on clinical disease activity and B-cell in patients with systemic lupus erythematosus. Ann Rheum Dis 74(Suppl 2):1074.1-1074CrossRef

35.

Monserrat J, Perez A, Moruno H, et al (2016) Long term immunomodulatory effect in circulating B cell compartment of belimumab treated systemic lupus erythematosus patients. Clin Exp Rheumatol 34(4):S63. https://www.embase.com/records?subaction=viewrecord&rid=1&page=1&id=L615008508

36.

Aldasoro V, Varela M, Mendizabal J, Garrido L, Fito C, del Val N, Gutiérrez R, Paniagua I, Horcada L, Ibáñez R (2018) PS7:140 belimumab in systemic lupus erythematosus 1 year of follow up. Lupus Sci Med 5(Suppl 1):A104–A105

37.

Riancho-Zarrabeitia L, Villa Blanco I, Santos-Gómez M, Aurrecoechea E (2018) Belimumab en lupus eritematoso sistémico: experiencia en práctica clínica en un hospital comarcal. Reumatol Clínica.https://linkinghub.elsevier.com/retrieve/pii/S1699258X1830041X

38.

Argumánez CM, Rusinovich O, Giráldez CR et al (2019) AB0475 belimumab: experience in clinical practice settings at a rheumatology department in a tertiary hospital. BMJ p. 1701.2–1702.

39.

Anjo C, Mascaró Jr J-M, Espinosa G, Cervera R (2019) Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scand J Rheumatol 48(6):469–73. http://www.ncbi.nlm.nih.gov/pubmed/31264525

40.

Alonso Castro V, Gonzalez Martin C, Sanchez Guerrero A, TorralbaArranz A (2019) DI-005 use of belimumab for the treatment of systemic lupus erythematosus in a tertiary level hospital. Eur J Hosp Pharm 21(Suppl 1):A71.3-A72. https://doi.org/10.1136/ejhpharm-2013-000436.176CrossRef

41.

AlmanchelRivadeneyra M, Pellicer Franco C, Muñoz Contreras C et al (2014) CP-006 effectiveness and safety of belimumab for systemic lupus erythematosus. Eur J Hosp Pharm 21(Suppl 1):A2.3-A3. https://doi.org/10.1136/ejhpharm-2013-000436.6CrossRef

42.

Brito Zeron P, Caminal-Montero L, Chamorro A et al (2014) AB0542 blocking the human B lymphocyte stimulator molecule (BLYS) using a monoclonal antibody (belimumab) in systemic lupus erythematosus: first results in real-life Spanish patients with refractory disease (Biogeas-Semi Registry). Ann Rheum Dis 73(Suppl 2):985.2-985. https://doi.org/10.1136/annrheumdis-2014-eular.5447CrossRef

43.

Fanouriakis A, Kostopoulou M, Alunno A et al (2019) Update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. Ann Rheum Dis 78(6):736–745. https://doi.org/10.1136/annrheumdis-2019-eular.3117

44.

Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43(8):1801–8. https://pubmed.ncbi.nlm.nih.gov/10943870/

45.

Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S (2019) Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis 78(3):372–379. https://doi.org/10.1136/annrheumdis-2018-214043CrossRefPubMed

46.

Furie R, Petri M, Zamani O et al (2011) A phase III randomized placebo-controlled study of Belimumab a monoclonal antibody that inhibits B lymphocyte stimulator in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–30. https://doi.org/10.1002/art.30613CrossRefPubMedPubMedCentral

47.

Iaccarino L, Saccon F, Mathieu A et al (2019) FRI0199 effectiveness and safety of belimumab in patients with active systemic lupus erythematosus: results from a large, nationwide, multicentric study. BMJ :778–9. https://doi.org/10.1136/annrheumdis-2019-eular.3635

48.

Furer V, Zisman D, Pokroy-Shapira E, Molad Y, Elkayam O, Paran D (2016) Systemic lupus erythematosus exacerbation following cessation of belimumab treatment. Scand J Rheumatol 45(2):103–106CrossRef

49.

Bae S, Dimelow R, Ji B, Kurrasch R, Muzaffar S, Punwaney R, Roth D, Stober P, Song Y, Xie W ZF (2019) Results of the open-label, non-randomized 52-week study to evaluate treatment holidays and rebound phenomenon after treatment with belimumab in patients with SLE. Arthritis Rheumatol. https://acrabstracts.org/abstract/results-of-the-open-label-non-randomized-52-week-study-to-evaluate-treatment-holidays-and-rebound-phenomenon-after-treatment-with-Belimumab-in-patients-with-sle/

50.

Furie RA, Wallace DJ, Aranow C et al (2018) Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six–week phase III parent study in the United States. Arthritis Rheumatol 70(6):868–77. https://doi.org/10.1002/art.40439CrossRefPubMedPubMedCentral

51.

Van Vollenhoven RF, Petri MA, Cervera R et al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71(8):1343–9. https://doi.org/10.1136/annrheumdis-2011-200937CrossRefPubMed

52.

Cevey M, Calvo-Alén J, Crespo C, Robles-Marhuenda A, Smolen L, Cortés-Hernández J (2019) Budget impact analysis of subcutaneous belimumab in patients with systemic lupus erythematosus in Spain. Clin Outcomes Res Volume 11:757–65. https://www.dovepress.com/budget-impact-analysis-of-subcutaneous-Belimumab-in-patients-with-syst-peer-reviewed-article-CEOR

53.

Fabris M, De Marchi G, Domenis R, Caponnetto F, Guella S, Dal Secco C, Cabas N, De Vita S, Beltrami AP, Curcio F, Quartuccio L (2022) High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. J Autoimmun 129:102827. https://doi.org/10.1016/j.jaut.2022.102827CrossRefPubMedPubMedCentral

Title: Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients
Authors: Carlos Rodríguez Escalera
Ángela María Zurita Guisado
Francisco Javier Mateo
Noemí Bahamontes-Rosa
María Jesús García Villanueva
Publication date: 23-07-2022
Publisher: Springer International Publishing
Keywords: Systemic Lupus Erythematosus
Lupus Nephritis
Published in: Clinical Rheumatology / Issue 11/2022
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-022-06287-9

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2022

The correlation of ultrasound-detected synovitis in an individual small joint with overall clinical disease activity in patients with rheumatoid arthritis

Anti-Ro52/TRIM21 serological subsets identify differential clinical and laboratory parameters

Clinical characteristics and outcomes of digital gangrene in connective tissue disorders: a longitudinal single-centre experience from Jodhpur, India

Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients

Correction to: Immunoglobulin G4–related coronary periarteritis: a systematic literature review with a case series

Predicting bacterial infection risk in patients with ANCA-associated vasculitis in southwest China: development of a new nomogram

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage